STOCK TITAN

[Form 4] SANGAMO THERAPEUTICS, INC Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Sangamo Therapeutics (SGMO) reported an insider transaction on Form 4. The company’s SVP, Chief Legal Officer and Secretary executed a tax-withholding disposition tied to RSU vesting on 10/22/2025. 44,122 shares of common stock were withheld (code F) at $0.66 per share using the issuer’s closing price. Following the transaction, the reporting person beneficially owns 704,121 shares, held directly.

The filing notes these shares were surrendered solely to cover taxes upon vesting under the Amended and Restated 2018 Equity Incentive Plan and do not reflect an open-market sale. It also outlines remaining RSU vesting schedules, including portions from grants dated 1/22/2024, 2/24/2023, and 2/25/2025, subject to continuous service and plan terms.

Sangamo Therapeutics (SGMO) ha riportato una transazione da insider su Form 4. Il Senior Vice President, Direttore Legale e Segretario dell'azienda ha eseguito una disposizione per ritenuta fiscale legata alla maturazione degli RSU il 22/10/2025. 44.122 azioni ordinarie sono state trattenute (codice F) a $0,66 per azione utilizzando il prezzo di chiusura dell'emittente. A seguito della transazione, la persona che segnala detiene beneficiariamente 704.121 azioni, detenute direttamente.

La dichiarazione nota che queste azioni sono state consegnate esclusivamente per coprire le tasse al vesting ai sensi del Piano di incentivazione azionaria modificato e riordinato 2018 e non riflettono una vendita sul mercato aperto. Descrive inoltre i rimanenti piani di vesting RSU, comprese porzioni provenienti da grant datati 1/22/2024, 2/24/2023 e 2/25/2025, soggetti a servizio continuo e ai termini del piano.

Sangamo Therapeutics (SGMO) informó de una transacción de insider en Formulario 4. El SVP, Director Legal y Secretario de la empresa ejecutó una disposición de retención de impuestos vinculada al vesting de RSU el 22/10/2025. 44.122 acciones ordinarias fueron retenidas (código F) a $0,66 por acción utilizando el precio de cierre de la emisora. Tras la transacción, la persona que reporta posee beneficiosamente 704.121 acciones, directamente en propiedad.

La presentación señala que estas acciones se entregaron únicamente para cubrir impuestos al vesting conforme al Plan de Incentivo de Equidad de 2018 enmendado y restated y no reflejan una venta en el mercado abierto. También describe los calendarios de vesting RSU restantes, incluyendo porciones de donaciones fechadas 1/22/2024, 2/24/2023 y 2/25/2025, sujetos a servicio continuo y a los términos del plan.

Sangamo Therapeutics (SGMO)가 Form 4에서 내부자 거래를 보고했습니다. 회사의 SVP 겸 최고법무책임자이자 비서가 2025년 10월 22일 RSU의 취득에 따른 세금 원천 처분을 실행했습니다. 44,122주의 보통주가 원천 징수되었고(코드 F) 주당 $0.66의 발행자 종가로 계산되었습니다. 거래 후 보고자 보유 주식은 704,121주로 직접 보유합니다.

해당 서류에 따르면 이 주식은 2018년 수정 및 재구성된 주식 보상 계획에 따른 vesting를 충당하기 위해서만 양도되었으며 공개시장 매도를 반영하지 않습니다. 또한 RSU 남은 vesting 일정과 2024/1/22, 2023/2/24, 2025/2/25에 해당하는 그랜트 portions를 포함하고 있으며 지속적인 근무와 계획 조건에 따른다는 점도 설명합니다.

Sangamo Therapeutics (SGMO) a signalé une transaction d’initié sur Form 4. Le vice-président principal, Directeur juridique et Secrétaire de l’entreprise a exécuté une disposition de retenue fiscale liée à la prise de vesting des RSU le 22/10/2025. 44 122 actions ordinaires ont été retenues (code F) à $0,66 par action en utilisant le cours de clôture de l’émetteur. Suite à la transaction, la personne qui déclare détient bénéfi ci aisement 704 121 actions, détenues directement.

Le dépôt indique que ces actions ont été remises uniquement pour couvrir les impôts lors du vesting en vertu du Plan incitatif d’équité 2018 modifié et réorganisé et n’impliquent pas une vente sur le marché libre. Il décrit également les calendriers de vesting RSU restants, y compris des portions des attributions datées du 22/01/2024, 24/02/2023 et 25/02/2025, soumis à une prestation de service continue et aux termes du plan.

Sangamo Therapeutics (SGMO) meldete eine Insider-Transaktion auf Formular 4. Der Senior Vice President, Chief Legal Officer und Secretary des Unternehmens führte eine steuerliche Abzug-Disposition an RSU-Vesting am 22.10.2025 durch. 44.122 Aktien der Stammaktien wurden einbehalten (Code F) zu $0,66 pro Aktie unter Verwendung des Schlusskurses des Emittenten. Nach der Transaktion besitzt die meldende Person vorteilhaft 704.121 Aktien, direkt gehalten.

Das Filing vermerkt, dass diese Aktien ausschließlich zur Abdeckung von Steuern beim Vesting gemäß dem Amended and Restated 2018 Equity Incentive Plan übergeben wurden und keinen offenen Marktverkauf widerspiegeln. Es beschreibt außerdem verbleibende RSU-Vesting-Pläne, einschließlich Teile aus Zuschüssen vom 22.01.2024, 24.02.2023 und 25.02.2025, vorbehaltlich kontinuierlicher Dienstzeit und Planbedingungen.

Sangamo Therapeutics (SGMO) أبلغت عن صفقة داخلية في النموذج 4. نفذ نائب رئيس مجلس الإدارة الأول، المدير القانوني والسكيرتير للشركة ترتيب حجز ضرائب مرتبطًا بإنجاز RSU في 22/10/2025. 44,122 سهماً عاديًا حُجِزت (رمز F) عند $0.66 للسهم باستخدام سعر الإغلاق للمصدر. بعد الصفقة، يملك الشخص المبلغ تقريره بشكل Beneficial 704,121 سهماً بشكل مباشر.

تشير الإيداع إلى أن هذه الأسهم سُلِّمت فقط لتغطية الضرائب عند vesting وفقًا لـ Plan Incentive Equity المعدل والمعاد تنظيمه لعام 2018 ولا تعكس بيعًا في السوق المفتوحة. كما يوضح جداول vesting RSU المتبقية، بما في ذلك أجزاء من منح بتاريخ 1/22/2024 و2/24/2023 و2/25/2025، رهناً بخدمة مستمرة وبشروط الخطة.

Positive
  • None.
Negative
  • None.

Sangamo Therapeutics (SGMO) ha riportato una transazione da insider su Form 4. Il Senior Vice President, Direttore Legale e Segretario dell'azienda ha eseguito una disposizione per ritenuta fiscale legata alla maturazione degli RSU il 22/10/2025. 44.122 azioni ordinarie sono state trattenute (codice F) a $0,66 per azione utilizzando il prezzo di chiusura dell'emittente. A seguito della transazione, la persona che segnala detiene beneficiariamente 704.121 azioni, detenute direttamente.

La dichiarazione nota che queste azioni sono state consegnate esclusivamente per coprire le tasse al vesting ai sensi del Piano di incentivazione azionaria modificato e riordinato 2018 e non riflettono una vendita sul mercato aperto. Descrive inoltre i rimanenti piani di vesting RSU, comprese porzioni provenienti da grant datati 1/22/2024, 2/24/2023 e 2/25/2025, soggetti a servizio continuo e ai termini del piano.

Sangamo Therapeutics (SGMO) informó de una transacción de insider en Formulario 4. El SVP, Director Legal y Secretario de la empresa ejecutó una disposición de retención de impuestos vinculada al vesting de RSU el 22/10/2025. 44.122 acciones ordinarias fueron retenidas (código F) a $0,66 por acción utilizando el precio de cierre de la emisora. Tras la transacción, la persona que reporta posee beneficiosamente 704.121 acciones, directamente en propiedad.

La presentación señala que estas acciones se entregaron únicamente para cubrir impuestos al vesting conforme al Plan de Incentivo de Equidad de 2018 enmendado y restated y no reflejan una venta en el mercado abierto. También describe los calendarios de vesting RSU restantes, incluyendo porciones de donaciones fechadas 1/22/2024, 2/24/2023 y 2/25/2025, sujetos a servicio continuo y a los términos del plan.

Sangamo Therapeutics (SGMO)가 Form 4에서 내부자 거래를 보고했습니다. 회사의 SVP 겸 최고법무책임자이자 비서가 2025년 10월 22일 RSU의 취득에 따른 세금 원천 처분을 실행했습니다. 44,122주의 보통주가 원천 징수되었고(코드 F) 주당 $0.66의 발행자 종가로 계산되었습니다. 거래 후 보고자 보유 주식은 704,121주로 직접 보유합니다.

해당 서류에 따르면 이 주식은 2018년 수정 및 재구성된 주식 보상 계획에 따른 vesting를 충당하기 위해서만 양도되었으며 공개시장 매도를 반영하지 않습니다. 또한 RSU 남은 vesting 일정과 2024/1/22, 2023/2/24, 2025/2/25에 해당하는 그랜트 portions를 포함하고 있으며 지속적인 근무와 계획 조건에 따른다는 점도 설명합니다.

Sangamo Therapeutics (SGMO) a signalé une transaction d’initié sur Form 4. Le vice-président principal, Directeur juridique et Secrétaire de l’entreprise a exécuté une disposition de retenue fiscale liée à la prise de vesting des RSU le 22/10/2025. 44 122 actions ordinaires ont été retenues (code F) à $0,66 par action en utilisant le cours de clôture de l’émetteur. Suite à la transaction, la personne qui déclare détient bénéfi ci aisement 704 121 actions, détenues directement.

Le dépôt indique que ces actions ont été remises uniquement pour couvrir les impôts lors du vesting en vertu du Plan incitatif d’équité 2018 modifié et réorganisé et n’impliquent pas une vente sur le marché libre. Il décrit également les calendriers de vesting RSU restants, y compris des portions des attributions datées du 22/01/2024, 24/02/2023 et 25/02/2025, soumis à une prestation de service continue et aux termes du plan.

Sangamo Therapeutics (SGMO) meldete eine Insider-Transaktion auf Formular 4. Der Senior Vice President, Chief Legal Officer und Secretary des Unternehmens führte eine steuerliche Abzug-Disposition an RSU-Vesting am 22.10.2025 durch. 44.122 Aktien der Stammaktien wurden einbehalten (Code F) zu $0,66 pro Aktie unter Verwendung des Schlusskurses des Emittenten. Nach der Transaktion besitzt die meldende Person vorteilhaft 704.121 Aktien, direkt gehalten.

Das Filing vermerkt, dass diese Aktien ausschließlich zur Abdeckung von Steuern beim Vesting gemäß dem Amended and Restated 2018 Equity Incentive Plan übergeben wurden und keinen offenen Marktverkauf widerspiegeln. Es beschreibt außerdem verbleibende RSU-Vesting-Pläne, einschließlich Teile aus Zuschüssen vom 22.01.2024, 24.02.2023 und 25.02.2025, vorbehaltlich kontinuierlicher Dienstzeit und Planbedingungen.

Sangamo Therapeutics (SGMO) أبلغت عن صفقة داخلية في النموذج 4. نفذ نائب رئيس مجلس الإدارة الأول، المدير القانوني والسكيرتير للشركة ترتيب حجز ضرائب مرتبطًا بإنجاز RSU في 22/10/2025. 44,122 سهماً عاديًا حُجِزت (رمز F) عند $0.66 للسهم باستخدام سعر الإغلاق للمصدر. بعد الصفقة، يملك الشخص المبلغ تقريره بشكل Beneficial 704,121 سهماً بشكل مباشر.

تشير الإيداع إلى أن هذه الأسهم سُلِّمت فقط لتغطية الضرائب عند vesting وفقًا لـ Plan Incentive Equity المعدل والمعاد تنظيمه لعام 2018 ولا تعكس بيعًا في السوق المفتوحة. كما يوضح جداول vesting RSU المتبقية، بما في ذلك أجزاء من منح بتاريخ 1/22/2024 و2/24/2023 و2/25/2025، رهناً بخدمة مستمرة وبشروط الخطة.

Sangamo Therapeutics (SGMO) 报告了在 Form 4 的内部人交易。公司的高级副总裁、首席法务官兼秘书于 2025-10-22 执行了与 RSU 授予归属相关的代扣税处分。44,122 股普通股被扣留(代码 F),按发行方收盘价 $0.66/股计算。交易后,申报人实际拥有 704,121 股,直接持有。

filing 指出这些股票仅用于在归属时覆盖税款,依据经修订并重新整理的 2018 股权激励计划,不反映公开市场出售。还概述了剩余的 RSU 归属计划,包括 2024-01-22、2023-02-24 和 2025-02-25 的部分授予,需持续服务并符合计划条款。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Willoughby Scott B.

(Last) (First) (Middle)
C/O SANGAMO THERAPEUTICS, INC.
501 CANAL BLVD.

(Street)
RICHMOND CA 94084

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SANGAMO THERAPEUTICS, INC [ SGMO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, CHIEF LEGAL OFFICER, SECY
3. Date of Earliest Transaction (Month/Day/Year)
10/22/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/22/2025 F 44,122(1) D $0.66 704,121(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on October 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on October 22, 2025 of $0.66/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
2. Includes: (a) 44,940 shares resulting from the October 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 89,063 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 8,016 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
/s/ Scott Willoughby 10/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did SGMO disclose on Form 4?

An officer reported a tax-withholding disposition of 44,122 shares (code F) on 10/22/2025 tied to RSU vesting.

What price was used for the SGMO tax withholding shares?

The issuer’s closing price of $0.66 per share on 10/22/2025.

How many SGMO shares does the insider hold after the transaction?

The insider beneficially owns 704,121 shares, held directly.

Was this an open-market sale of SGMO shares?

No. The shares were surrendered solely for mandatory tax withholding under the 2018 Equity Incentive Plan.

Which RSU grants are referenced in the SGMO filing?

Grants dated 1/22/2024, 2/24/2023, and 2/25/2025, with vesting subject to continuous service and plan terms.

What is the insider’s role at SGMO?

The reporting person is SGMO’s SVP, Chief Legal Officer, and Secretary.
Sangamo Therapeutics Inc

NASDAQ:SGMO

SGMO Rankings

SGMO Latest News

SGMO Latest SEC Filings

SGMO Stock Data

198.16M
294.97M
2.16%
16.96%
4.96%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
RICHMOND